Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Target Price at $9.66

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) have received a consensus recommendation of “Hold” from the nine analysts that are covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $9.66.

A number of research firms have issued reports on RVNC. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. HC Wainwright reiterated a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. StockNews.com initiated coverage on shares of Revance Therapeutics in a research report on Wednesday, December 4th. They set a “hold” rating for the company. Finally, Barclays reaffirmed an “equal weight” rating and issued a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th.

Revance Therapeutics Stock Down 20.7 %

Shares of Revance Therapeutics stock opened at $3.03 on Friday. The company has a market capitalization of $317.85 million, a P/E ratio of -1.57 and a beta of 0.82. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $9.74. The company has a 50 day moving average of $4.73 and a 200 day moving average of $4.48.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. As a group, research analysts anticipate that Revance Therapeutics will post -1.54 earnings per share for the current fiscal year.

Institutional Trading of Revance Therapeutics

Institutional investors have recently bought and sold shares of the stock. LMR Partners LLP acquired a new position in Revance Therapeutics in the third quarter worth $11,648,000. Integral Health Asset Management LLC acquired a new position in Revance Therapeutics in the second quarter worth $1,285,000. Vanguard Group Inc. boosted its stake in Revance Therapeutics by 6.5% in the first quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company’s stock worth $26,560,000 after purchasing an additional 328,781 shares in the last quarter. Alpine Associates Management Inc. acquired a new position in Revance Therapeutics in the third quarter worth $21,605,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Revance Therapeutics by 28.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 69,361 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 15,496 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.